Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Category Archives: Recombinant Antibody R&D

An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound

October 14, 2022Recombinant Antibody R&D, Therapeutic Antibody R&Dtherapeutic antibodybiorab

In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…

Alternatives to Cope with Lengthy Clinical Development Process for COVID-19

April 5, 2020News, Recombinant Antibody R&DClinical Development, SARS-CoV-2, therapeutic antibodybiorab

The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…

A Brief Introduction of MERS-CoV

February 21, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

In 2012, MERS-CoV (Middle East Respiratory Syndrome Coronavirus) was found in Saudi Arabia. The early labor symptoms caused by the viruse are similar to SARS (Severe Acute Respiratory Syndrome). Therefore, MERS-CoV isRead More…

Focus on SARS-CoV-2

February 19, 2020Recombinant Antibody R&DCoronavirus, COVID-19, SARS-CoV-2biorab

As we all know, a new crown pneumonia epidemic suddenly swept China at the end of 2019 and even affected the whole world. On January 30, 2020, WHO announced that the epidemicRead More…

Do You Know SARS-CoV ?

February 18, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

In 2002, severe acute respiratory syndrome occurred in Guangdong, China, and spread throughout the world, causing a global epidemic of infectious diseases. The culprit of this incident was SARS-CoV (Severe Acute RespiratoryRead More…

What is Coronavirus ?

February 17, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

Recently, a virus called SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) caused an epidemic with pneumonia as the main symptom. This SARS-CoV-2 is a coronavirus, so what exactly is a coronavirus? OverviewRead More…

Antibody Combo Expands Response to Checkpoint Inhibitor in Mice

May 24, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dantibody discovery, checkpoints, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…

Breakthrough Enables Screening Millions of Human Antibodies for New Drug Discovery

May 24, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dantibody discovery, antibody screening, monoclonal antibody drug, therapeutic antibodybiorab

“A new article outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specificallyRead More…

Development History of Keytruda (Pembrolizumab)

May 24, 2018News, Recombinant Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

Keytruda (pembrolizumab) is a drug developed by Merck (or MSD outside of the U.S. and Canada). It has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of aRead More…

FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors

January 4, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dmonoclonal antibody drugbiorab

“Emicizumab (trade name Hemlibra, emicizumab–kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting Factors IXa and X. On November 16, 2017, the drug (emicizumab–kxwh) was approved by Food and Drug Administration (FDA) approved to preventRead More…

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors
  • Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations
  • The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients
  • Scientists Discovered the Key Molecule Triggering Cancer Metastasis
  • Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Designed and Developed by templatesnext